ADC Therapeutics SA Price to Sales Ratio 2019-2022 | ADCT

Historical PS ratio values for ADC Therapeutics SA (ADCT) over the last 10 years. The current P/S ratio for ADC Therapeutics SA as of January 27, 2023 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ADC Therapeutics SA P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2023-01-27 5.05 2.49
2022-09-30 4.82 $2.03 2.38
2022-06-30 7.95 $1.22 6.50
2022-03-31 14.69 $1.05 14.03
2021-12-31 20.20 $0.44 45.71
2021-09-30 27.16 $0.22 123.27
2021-06-30 24.35 $0.05 496.90
2021-03-31 24.41 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.363B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00